Balance Sheet
Liabilities and Shareholders Equity
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Total Current Liabilities (2017 - 2024)

KalVista Pharmaceuticals' Total Current Liabilities history spans 10 years, with the latest figure at $26.1 million for Q4 2024.

  • For Q4 2024, Total Current Liabilities changed N/A year-over-year to $26.1 million; the TTM value through Dec 2024 reached $26.1 million, changed N/A, while the annual FY2024 figure was $22.8 million, N/A changed from the prior year.
  • Total Current Liabilities for Q4 2024 was $26.1 million at KalVista Pharmaceuticals, up from $22.2 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $26.1 million in Q4 2024 and bottomed at $6.5 million in Q1 2021.
  • The 4-year median for Total Current Liabilities is $15.9 million (2023), against an average of $15.5 million.
  • The largest annual shift saw Total Current Liabilities plummeted 57.23% in 2020 before it skyrocketed 58.58% in 2024.
  • A 4-year view of Total Current Liabilities shows it stood at $9.5 million in 2020, then crashed by 31.65% to $6.5 million in 2021, then skyrocketed by 172.34% to $17.8 million in 2023, then surged by 47.11% to $26.1 million in 2024.
  • Per Business Quant, the three most recent readings for KALV's Total Current Liabilities are $26.1 million (Q4 2024), $22.2 million (Q4 2024), and $22.4 million (Q3 2024).